Study to evaluate safety and efficacy of AB-101 in autoimmune diseases
Research type
Research Study
Full title
An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases
IRAS ID
1012474
Contact name
Chanel Mansfield
Contact email
Sponsor organisation
Artiva Biotherapeutics, Inc.
Clinicaltrials.gov Identifier
Research summary
This is a Phase 2a, open-label, muti-center study to evaluate the safety and tolerability of AB-101 administered in combination with rituximab after B-cell depleting antibody in adult participants with relapsing forms of B-cell dependent rheumatologic diseases.
B-cells are immune white blood cell, responsible for making antibodies. Antibodies are immune system proteins responsible for recognising and removing pathogens from the body.
AB-101 is a non-genetically modified, cryopreserved cord blood-derived natural killer (NK)-cell therapy created by Artiva
Biotherapeutics.
The combination of AB-101 and a B-cell depleting antibody treatments (e.g., rituximab, obinutuzumab) may be an effective method for better B-cell depletion.
Thus, provide meaningful and long-lasting clinical response in patients with advanced proliferative lupus nephritis or other forms of refractory SLE.
Study participation will last 4 years and will involve blood and urine tests, CT and ECHO/MUGA scans as well as other safety tests.REC name
North East - York Research Ethics Committee
REC reference
25/NE/0120
Date of REC Opinion
10 Sep 2025
REC opinion
Further Information Unfavourable Opinion